Media Coverage

KindredBio promotes Denise Bevers to president


Oct 25, 2018 - Animal Pharm
By Joseph Harvey

Kindred Biosciences' co-founder and chief operating officer Denise Bevers has been elevated to the role of president.

She has also been added to the board of the San Francisco-based business, which specializes in developing therapeutics for companion animals.

Ms Bevers founded KindredBio in 2012 with the firm's current chief executive Richard Chin and has since assumed positions of increasing responsibility at the firm. In her new role as president, Ms Bevers will oversee KindredBio's operational functions.

She will also retain her title as chief operating officer and continue to oversee the company's growing commercial organization. KindredBio is currently ramping up sales of its first product –  Mirataz (mirtazapine transdermal ointment).

Ms Bevers has over 20 years of experience in the areas of pharmaceuticals and R&D – knowledge that has led her to begin transferring innovation from the human pharma space to the companion animal market. Previously, she has managed multiple product launches and development programs from phase I through to phase IV.

Prior to KindredBio, Ms Bevers held leadership positions at Elan Pharmaceuticals, Scripps Clinic and Research Foundation, Quintiles and SkyePharma. Her role before co-founding KindredBio, was president and founding partner of SD Scientific – a medical affairs and communications company. 

Reprinted with permission of Animal Pharm News

Share

Search

Archive

News Releases

Inside the Corridor

KC Animal Health Blog

Investment Forum